Olympus receives FDA clearance for Narrow Band Imaging

Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, among other core businesses, announced today FDA 510(k) clearance of Narrow Band Imaging® (NBI) as enabling effective targeting of biopsies not seen under white light and improved visualization of tumor boundaries in Non-Muscle-Invasive Bladder Cancer (NMIBC) patients.

Based on a weighted average, the aggregated FDA-reviewed studies show NBI has visualized NMIBC lesions in:

  • 17 percent additional patients when compared with white light
  • 24 percent additional tumors
  • 28 percent additional carcinoma in situ (CIS or difficult-to-detect flat lesions)

This finding provides new treatment opportunities for urologists both in-office and in the O.R. Additionally, it offers the potential for improved cost reduction and better patient outcomes resulting from earlier detection.

NBI is the world's only patented endoscopic light technology that enables effective targeting of biopsies not seen under white light without the use of dyes or drugs. NBI is not intended to replace histopathological sampling as a means of diagnosis. NBI enhances visibility of vascular structures on the mucosal surface. Unlike white light, which uses all colors in the spectrum, NBI uses only blue and green. Blue and green light are strongly absorbed by blood and appear darker than normal tissue. Blue light (415nm) highlights the shallow capillaries and green light (540nm) highlights deeper veins. NBI's potential visualization of bladder cancer symptoms has been acknowledged by the medical community, but in 2013 a meta-analysis reviewed more than 30 disparate studies on the topic, enough to submit to the FDA.

"The detection of occult lesions in patients with de novo and recurrent bladder cancer results in markedly improved outcomes," said Daniel Canter, M.D., Vice Chairman of the Urologic Institute of Southeastern Pennsylvania and the Department of Urology of the Einstein Healthcare Network and Associate Professor at The Fox Chase Cancer Center. "An improved view into the underlying vascularity of the lining of the bladder means an improved ability to detect and treat not just the visible, obvious tumors but also the lesions that may have been missed with traditional white light cystoscopy only. This is something most urologists have known and would agree with, but it is now backed by the FDA, which should translate into improved patient care."

Bladder cancer is the sixth most common cancer in the United States, with the highest lifetime treatment costs per patient of all cancers. White light cystoscopy misses small papillary tumors or CIS at an estimated rate of 10-20 percent. Fifty-four percent of patients who go undiagnosed with CIS will progress to muscle invasive disease and require bladder removal (cystectomy) and a urinary diversion or neobladder. Ninety-six percent of patients diagnosed early will survive five years later. Bladder cancer is known to recur 50 percent of the time.




Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Evident Corporation - Life Sciences. (2019, June 20). Olympus receives FDA clearance for Narrow Band Imaging. News-Medical. Retrieved on July 13, 2024 from https://www.news-medical.net/news/20141215/Olympus-receives-FDA-clearance-for-Narrow-Band-Imaging.aspx.

  • MLA

    Evident Corporation - Life Sciences. "Olympus receives FDA clearance for Narrow Band Imaging". News-Medical. 13 July 2024. <https://www.news-medical.net/news/20141215/Olympus-receives-FDA-clearance-for-Narrow-Band-Imaging.aspx>.

  • Chicago

    Evident Corporation - Life Sciences. "Olympus receives FDA clearance for Narrow Band Imaging". News-Medical. https://www.news-medical.net/news/20141215/Olympus-receives-FDA-clearance-for-Narrow-Band-Imaging.aspx. (accessed July 13, 2024).

  • Harvard

    Evident Corporation - Life Sciences. 2019. Olympus receives FDA clearance for Narrow Band Imaging. News-Medical, viewed 13 July 2024, https://www.news-medical.net/news/20141215/Olympus-receives-FDA-clearance-for-Narrow-Band-Imaging.aspx.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
2023 EVIDENT Organoid Conference to share the latest organoid innovations